Giant Cell Arteritis

Interleukin 12 and interleukin 23 play key pathogenic roles in inflammatory and proliferative pathways in giant cell arteritis
Richard Conway, Lorraine O’Neill, Geraldine M McCarthy, Conor C Murphy, Aurelie Fabre, Susan Kennedy, Douglas J Veale, Sarah M Wade, Ursula Fearon, Eamonn S Molloy

Annals of the Rheumatic Diseases Dec 2018, 77 (12) 1815-1824; DOI: 10.1136/annrheumdis-2018-213488
Platelet activation, as measured by plasma soluble glycoprotein VI, is not associated with disease activity or ischaemic events in giant cell arteritis
Richard Conway, Anne Madigan, Niamh Redmond, Laura Helbert, Eamonn S Molloy, Eimear Dunne, Dermot Kenny, Geraldine McCarthy

Annals of the Rheumatic Diseases Nov 2018, 77 (11) 1695-1697; DOI: 10.1136/annrheumdis-2018-213487
Utility of PET/CT in the diagnosis of inflammatory rheumatic diseases: a systematic review and meta-analysis
Lucie Descamps, Louis Olagne, Charles Merlin, Florent Cachin, Martin Soubrier, Sylvain Mathieu

Annals of the Rheumatic Diseases Nov 2018, 77 (11) e81; DOI: 10.1136/annrheumdis-2017-212660
Artery tertiary lymphoid organs in giant cell arteritis are not exclusively located in the media of temporal arteries
Jacoba Carolien Graver, Maria Sandovici, Arjan Diepstra, Annemieke M H Boots, Elisabeth Brouwer

Annals of the Rheumatic Diseases Mar 2018, 77 (3) e16; DOI: 10.1136/annrheumdis-2017-211860
Response to: ’Artery tertiary lymphoid organs in giant cell arteritis are not exclusively located in the media of temporal arteries' by Graver et al
Francesco Ciccia, Aroldo Rizzo, Carlo Salvarani, Giovanni Triolo

Annals of the Rheumatic Diseases Mar 2018, 77 (3) e17; DOI: 10.1136/annrheumdis-2017-211882
Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis
Georgina Espígol-Frigolé, Marc Corbera-Bellalta, Ester Planas-Rigol, Ester Lozano, Marta Segarra, Ana García-Martínez, Sergio Prieto-González, José Hernández-Rodríguez, Josep M Grau, Mahboob U Rahman, Maria C Cid

Annals of the Rheumatic Diseases Sep 2013, 72 (9) 1481-1487; DOI: 10.1136/annrheumdis-2012-201836
Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial
Raphaèle Seror, Gabriel Baron, Eric Hachulla, Michel Debandt, Claire Larroche, Xavier Puéchal, François Maurier, Benoît de Wazieres, Thomas Quéméneur, Philippe Ravaud, Xavier Mariette

Annals of the Rheumatic Diseases Dec 2014, 73 (12) 2074-2081; DOI: 10.1136/annrheumdis-2013-203586
Ustekinumab inhibits Th1 and Th17 polarisation in a patient with giant cell arteritis
Maxime Samson, Thibault Ghesquière, Sabine Berthier, Bernard Bonnotte

Annals of the Rheumatic Diseases Feb 2018, 77 (2) e6; DOI: 10.1136/annrheumdis-2017-211622
Response to: ustekinumab inhibits Th1 and Th17 polarisation in a giant-cell arteritis patient by Samson et al
Richard Conway, Ursula Fearon, Eamonn S Molloy

Annals of the Rheumatic Diseases Feb 2018, 77 (2) e7; DOI: 10.1136/annrheumdis-2017-211669
Influence of the IL17A locus in giant cell arteritis susceptibility
A Márquez, J Hernández-Rodríguez, M C Cid, R Solans, S Castañeda, M E Fernández-Contreras, M Ramentol, I C Morado, J Narváez, C Gómez-Vaquero, V M Martínez-Taboada, N Ortego-Centeno, B Sopeña, J Monfort, M J García-Villanueva, L Caminal-Montero, E de Miguel, R Blanco, Spanish GCA Consortium, O Palm, O Molberg, J Latus, N Braun, F Moosig, T Witte, L Beretta, A Santaniello, G Pazzola, L Boiardi, C Salvarani, M A González-Gay, J Martín

Annals of the Rheumatic Diseases Sep 2014, 73 (9) 1742-1745; DOI: 10.1136/annrheumdis-2014-205261

Main menu

Giant Cell Arteritis

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Giant Cell Arteritis

Pages